// App-Quantinova.ai

e17044 : Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).

Researchers

Presenter

  • Catherine Curran

Principal Investigators

  • Gregory Russell Pond

  • Pier Vitale Nuzzo

  • Sarah Abou Alaiwi

  • Amin Nassar

  • Xiao X. Wei

  • Kerry L. Kilbridge

  • Bradley Alexander McGregor

  • Praful Ravi

  • Arvind Ravi

  • Guru Sonpavde

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • McMaster University, Department of Surgery, Hamilton, ON, Canada

  • BIDMC, Brookline, MA

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Neutrophil lymphocyte ratio

Drug/Treatment

  • Angiotensin II

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved